References
- Dahl J. B., Kehlet H. Non‐steroidal anti‐inflammatory drugs: rationale for use in severe postoperative pain. Br. J. Pharmacol. 1991; 66: 703–712
- Dahl J. B. Postoperative analgesia; review. Acta Anaesthesiol. Scand. 2000; 44: 1–13, [CROSSREF]
- Gillis J. C., Brogden R. N. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997; 53: 139–188, [PUBMED], [INFOTRIEVE]
- DeAndrade J. R., Maslanka M., Maneatis T., Bynum L., Burchmore M. The use of ketorolac in the managment of postoperative pain. Orthopedics 1994; 17: 157–166, [PUBMED], [INFOTRIEVE], [CSA]
- Domer F. Characterization of the analgesic activity of ketorolac in mice. Eur. J. Pharmacol. 1990; 177: 127–135, [PUBMED], [INFOTRIEVE], [CROSSREF]
- United States Pharmacopeia 24/ National Formulary 19. United States Pharmacopeial Convention, Rockville, MD, 1999; 946
- Mroszczak E. J., Lee F. W., Combs D., Sarquist F. H., Huang B. L. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animal and humans. Drug Metab. Dispos. 1987; 15: 618–626, [PUBMED], [INFOTRIEVE]
- Loftsson T., Fridriksdottir H., Gudmundsdottir T. K. The effect of water‐soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 1996; 127: 293–296, [CROSSREF]
- , URL:http://www.basf.de/en/dispersionen/products/pvp (accessed June 2000)
- Malhotra M., Majumdar D. K. In vitro transcorneal permeation from oil based ocular drops and ophthalmic ointment. Indian J. Exp. Biol. 1997; 35: 1324–1330, [PUBMED], [INFOTRIEVE], [CSA]
- Chang, Hung‐Chih, Li, Lukchiu, Tian, Youqin. Butorphanol sustained release formulations. Unites States Patent 6,197,344, March 6, 2001
- Engstrom S., Lindahl L., Wallin R., Engblom J. A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar‐to‐cubic phase transition. Int. J. Pharm. 1992; 86: 137–145, [CROSSREF]
- Wyatt D. M. A cubic‐phase delivery system composed of glyceryl monooleate and water for sustained release of water‐soluble drugs. Pharm. Technol. 1992; 16: 116–122
- Shah J. C., Sadhale Y., Chilukuri D. M. Cubic phase gels as drug delivery systems. Adv. Drug Deliv. Rev. 2001; 47: 229–250, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Malonne H., Fontaine J., Moes A. In vitro/in vivo characterisation of a Tramadol HCl depot system composed of monoolein and water. Biol. Pharm. Bull. 2000; 23: 627–631, [PUBMED], [INFOTRIEVE], [CSA]
- Vogel H. G., Vogel W. H. Analgesia, antiinflammatory and antipyretic activity. Drug Discovery and Evaluation. Springer. 1997; 360–420
- Benita S., Friedman D., Weinstock M. Pharmacological evaluation of an injectable prolonged release emulsion of physostigmine in rabbits. J. Pharm. Pharmacol. 1986; 38: 653, [PUBMED], [INFOTRIEVE]
- Toradol® IV/IM Complete Product Information. Roche U.S. Pharmaceuticals. 2002
- Ritschel W. A. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Dev. Ind. Pharm. 1989; 15: 1073–1103
- Steinijans V. W. Pharmacokinetic characterisation of controlled‐release formulations. Eur. J. Drug Metab. Pharmacokinet. 1990; 15: 173–181, [PUBMED], [INFOTRIEVE]